Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue
Generated first quarter 2025 adjusted net income 1 of $7.7 million
Announced plans to acquire Fabric Genomics
Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025
GeneDx to host conference call today at 8:30 a.m. ET
GAITHERSBURG, Md., April 30, 2025 --( BUSINESS WIRE )--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025.
"Healthcare is at an inflection point where integrating genomic insights into standard care is becoming essential – both for better clinical outcomes and for saving the healthcare system valuable dollars," said Katherine Stueland, CEO of GeneDx. "The first quarter exceeded our expectations across all measures, headlined by 62% revenue growth in exome/genome and our third consecutive quarter of profitability, demonstrating the leverage in our business model to drive sustained, profitable growth. We are well positioned to transform genomic testing globally, driving improved outcomes on an even larger scale."
"Our business continued to exceed expectations, with volume growth accelerating throughout the quarter," said Kevin Feeley, CFO of GeneDx. "Looking forward, the combination of continued core momentum, the rolling expansion of new indications in the outpatient setting, and the recent launch of a new ultraRapid genome product are expected to drive incremental volume growth opportunities throughout the remainder of 2025 and beyond."
First Quarter 2025 Financial Results (Unaudited) 1
Revenues
Exome and genome volume
Gross margin
Operating expenses
Net Income
Cash position
(1) Adjusted gross margin, adjusted total operating expenses and adjusted net loss are non-GAAP financial measures. See appendix for a reconciliation of GAAP to Non-GAAP figures presented.
GeneDx Full Year 2025 Guidance
GeneDx has updated its full year 2025 guidance. Management expects GeneDx to deliver:
First Quarter 2025 Business Highlights
Driving sustainable growth and market leadership
Advancing the field to accelerate market expansion
Webcast and Conference Call Details
GeneDx will host a conference call today, April 30, 2025, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/ .
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance and our market opportunity, including our expected full year 2025 reported revenue and volume guidance, adjusted gross margin and our adjusted net income in 2025. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on February 20, 2025 and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn , Facebook , and Instagram .
|
Volume & Revenue |
|||||||||||||||
|
|
|||||||||||||||
|
|
1Q25 |
|
4Q24 |
|
3Q24 |
|
2Q24 |
|
1Q24 |
||||||
|
Volumes |
|
|
|
|
|
|
|
|
|
||||||
|
Whole exome, whole genome |
|
20,562 |
|
|
20,676 |
|
|
19,262 |
|
|
|
18,017 |
|
|
16,592 |
|
Hereditary cancer |
|
2,725 |
|
|
3,486 |
|
|
4,672 |
|
|
|
5,482 |
|
|
6,868 |
|
Other panels |
|
28,228 |
|
|
30,115 |
|
|
35,095 |
|
|
|
34,204 |
|
|
31,763 |
|
Total |
|
51,515 |
|
|
54,277 |
|
|
59,029 |
|
|
|
57,703 |
|
|
55,223 |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Revenue ($ millions) |
|
|
|
|
|
|
|
|
|
||||||
|
Whole exome, whole genome |
$ |
71.4 |
|
$ |
78.8 |
|
$ |
60.0 |
|
|
$ |
50.7 |
|
$ |
44.0 |
|
Hereditary cancer |
|
2.2 |
|
|
2.8 |
|
|
3.3 |
|
|
|
3.8 |
|
|
5.5 |
|
Other panels |
|
12.1 |
|
|
12.3 |
|
|
13.8 |
|
|
|
13.3 |
|
|
10.7 |
|
Data information |
|
1.4 |
|
|
1.4 |
|
|
(0.5 |
) |
|
|
1.1 |
|
|
1.3 |
|
Total |
$ |
87.1 |
|
$ |
95.3 |
|
$ |
76.6 |
|
|
$ |
68.9 |
|
$ |
61.5 |
|
Unaudited Select Financial Information (in thousands) |
|||||||||||
|
|
|||||||||||
|
|
Three months ended March 31, 2025 |
|
Three months ended December 31, 2024 |
||||||||
|
|
GeneDx |
|
Other 1 |
|
Total |
|
GeneDx |
|
Other 1 |
|
Total |
|
Revenue |
$87,115 |
|
$— |
|
$87,115 |
|
$95,286 |
|
$354 |
|
$95,640 |
|
Adjusted cost of services |
27,396 |
|
— |
|
27,396 |
|
28,384 |
|
— |
|
28,384 |
|
Adjusted gross profit (loss) |
$59,719 |
|
$— |
|
$59,719 |
|
$66,902 |
|
$354 |
|
$67,256 |
|
Adjusted gross margin % |
68.6% |
|
|
|
68.6% |
|
70.2% |
|
|
|
70.3% |
|
|
Three months ended March 31, 2024 |
||||
|
|
GeneDx |
|
Other 1 |
|
Total |
|
Revenue |
$61,461 |
|
$961 |
|
$62,422 |
|
Adjusted cost of services |
24,099 |
|
— |
|
24,099 |
|
Adjusted gross profit (loss) |
$37,362 |
|
$961 |
|
$38,323 |
|
Adjusted gross margin % |
60.8% |
|
|
|
61.4% |
|
|
|||||
|
(1) Other represents revenue and costs in 2024 associated with the shut down Legacy Sema4 diagnostic testing business. |
|||||
|
Three months ended March 31, 2025 |
||||||||||||||||||||||||||
|
|
Reported |
|
Depreciation and amortization |
|
Stock-based compensation expense |
|
Restructuring costs |
|
Change in FV of warrants |
|
Other 1 |
|
Adjusted |
|||||||||||||
|
Diagnostic test revenue |
$ |
85,759 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
$ |
— |
|
|
$ |
85,759 |
|
|
Other revenue |
|
1,356 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
1,356 |
|
|
Total revenue |
|
87,115 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
87,115 |
|
|
Cost of services |
|
28,639 |
|
|
|
(1,075 |
) |
|
|
(168 |
) |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
27,396 |
|
|
Gross profit |
|
58,476 |
|
|
|
1,075 |
|
|
|
168 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
59,719 |
|
|
Gross margin |
|
67.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
68.6 |
% |
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Research and development |
|
12,577 |
|
|
|
(372 |
) |
|
|
(419 |
) |
|
|
(28 |
) |
|
|
— |
|
|
— |
|
|
|
11,758 |
|
|
Selling and marketing |
|
18,316 |
|
|
|
(1,225 |
) |
|
|
(546 |
) |
|
|
(16 |
) |
|
|
— |
|
|
— |
|
|
|
16,529 |
|
|
General and administrative |
|
32,134 |
|
|
|
(3,006 |
) |
|
|
(2,850 |
) |
|
|
(514 |
) |
|
|
— |
|
|
(1,784 |
) |
|
|
23,980 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
(Loss) profit from operations |
|
(4,551 |
) |
|
|
5,678 |
|
|
|
3,983 |
|
|
|
558 |
|
|
|
— |
|
|
1,784 |
|
|
|
7,452 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Interest expense, net |
|
(640 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
640 |
|
|
|
— |
|
|
Other (expense) income, net |
|
(891 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,100 |
|
|
30 |
|
|
|
239 |
|
|
Income tax expense |
|
(447 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
447 |
|
|
|
— |
|
|
Net (loss) income |
$ |
(6,529 |
) |
|
$ |
5,678 |
|
|
$ |
3,983 |
|
|
$ |
558 |
|
|
$ |
1,100 |
|
$ |
2,901 |
|
|
$ |
7,691 |
|
|
|
Three months ended March 31, 2024 |
|||||||||||||||||||||||||
|
|
Reported |
|
Depreciation and amortization |
|
Stock-based compensation expense |
|
Restructuring costs |
|
Change in FV of warrants |
|
Other 1 |
|
Adjusted |
|||||||||||||
|
Diagnostic test revenue |
$ |
61,104 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
$ |
61,104 |
|
||
|
Other revenue |
|
1,318 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
1,318 |
|
|
Total revenue |
|
62,422 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
62,422 |
|
|
Cost of services |
|
25,011 |
|
|
|
(816 |
) |
|
|
(48 |
) |
|
|
(48 |
) |
|
|
— |
|
|
— |
|
|
|
24,099 |
|
|
Gross profit |
|
37,411 |
|
|
|
816 |
|
|
|
48 |
|
|
|
48 |
|
|
|
— |
|
|
— |
|
|
|
38,323 |
|
|
Gross margin |
|
59.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
61.4 |
% |
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Research and development |
|
11,567 |
|
|
|
(196 |
) |
|
|
187 |
|
|
|
(103 |
) |
|
|
— |
|
|
— |
|
|
|
11,455 |
|
|
Selling and marketing |
|
16,085 |
|
|
|
(1,225 |
) |
|
|
20 |
|
|
|
(400 |
) |
|
|
— |
|
|
— |
|
|
|
14,480 |
|
|
General and administrative |
|
23,419 |
|
|
|
(3,011 |
) |
|
|
292 |
|
|
|
(292 |
) |
|
|
— |
|
|
— |
|
|
|
20,408 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Loss from operations |
|
(13,660 |
) |
|
|
5,248 |
|
|
|
(451 |
) |
|
|
843 |
|
|
|
— |
|
|
— |
|
|
|
(8,020 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Interest expense, net |
|
(597 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
597 |
|
|
|
— |
|
|
Other (expense) income, net |
|
(6,064 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6,101 |
|
|
— |
|
|
|
37 |
|
|
Income tax benefit |
|
82 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
(82 |
) |
|
|
— |
|
|
Net loss |
$ |
(20,239 |
) |
|
$ |
5,248 |
|
|
$ |
(451 |
) |
|
$ |
843 |
|
|
$ |
6,101 |
|
$ |
515 |
|
|
$ |
(7,983 |
) |
|
|
Three months ended December 31, 2024 |
|||||||||||||||||||||||||
|
|
Reported |
|
Depreciation and amortization |
|
Stock-based compensation expense |
|
Restructuring costs |
|
Change in FV of warrants |
|
Other 1 |
|
Adjusted |
|||||||||||||
|
Diagnostic test revenue |
$ |
94,196 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
$ |
— |
|
|
$ |
94,196 |
|
|
Other revenue |
|
1,444 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
1,444 |
|
|
Total revenue |
|
95,640 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
95,640 |
|
|
Cost of services |
|
29,435 |
|
|
|
(928 |
) |
|
|
(123 |
) |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
28,384 |
|
|
Gross profit |
|
66,205 |
|
|
|
928 |
|
|
|
123 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
67,256 |
|
|
Gross margin |
|
69.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
70.3 |
% |
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Research and development |
|
11,588 |
|
|
|
(294 |
) |
|
|
(495 |
) |
|
|
(13 |
) |
|
|
— |
|
|
— |
|
|
|
10,786 |
|
|
Selling and marketing |
|
17,676 |
|
|
|
(1,225 |
) |
|
|
(347 |
) |
|
|
(30 |
) |
|
|
— |
|
|
— |
|
|
|
16,074 |
|
|
General and administrative |
|
27,350 |
|
|
|
(3,111 |
) |
|
|
(1,880 |
) |
|
|
(249 |
) |
|
|
— |
|
|
— |
|
|
|
22,110 |
|
|
Other, net |
|
785 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Profit from operations |
|
8,806 |
|
|
|
5,558 |
|
|
|
2,845 |
|
|
|
292 |
|
|
|
— |
|
|
— |
|
|
|
17,501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Interest expense, net |
|
(698 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
698 |
|
|
|
— |
|
|
Other (expense) income, net |
|
(2,694 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,980 |
|
|
666 |
|
|
|
(48 |
) |
|
Income tax benefit |
|
24 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
(24 |
) |
|
|
— |
|
|
Net income |
$ |
5,438 |
|
|
$ |
5,558 |
|
|
$ |
2,845 |
|
|
$ |
292 |
|
|
$ |
1,980 |
|
$ |
1,340 |
|
|
$ |
17,453 |
|
|
|
||||||||||||||||||||||||||
|
(1) Other represents interest expense, net, income tax (expense) benefit for all periods presented. Other for the three months ended March 31, 2025, includes transaction costs related to the planned acquisition of Fabric Genomics. Other for the three months ended December 31, 2024, includes legal costs related to a legal settlement. |
||||||||||||||||||||||||||
|
GeneDx Holdings Corp. |
|||||||
|
Condensed Consolidated Balance Sheets |
|||||||
|
(in thousands, except share and per share amounts) |
|||||||
|
|
|||||||
|
|
March 31, 2025 (Unaudited) |
|
December 31, 2024 |
||||
|
Assets: |
|
|
|
||||
|
Current assets: |
|
|
|
||||
|
Cash and cash equivalents |
$ |
99,704 |
|
|
$ |
85,212 |
|
|
Marketable securities |
|
59,456 |
|
|
|
55,973 |
|
|
Accounts receivable |
|
45,983 |
|
|
|
37,426 |
|
|
Inventory, net |
|
12,662 |
|
|
|
10,650 |
|
|
Prepaid expenses and other current assets |
|
8,011 |
|
|
|
8,707 |
|
|
Total current assets |
|
225,816 |
|
|
|
197,968 |
|
|
Operating lease right-of-use assets |
|
24,883 |
|
|
|
25,613 |
|
|
Property and equipment, net |
|
36,383 |
|
|
|
32,893 |
|
|
Intangible assets, net |
|
155,094 |
|
|
|
158,600 |
|
|
Other assets 1 |
|
4,254 |
|
|
|
4,306 |
|
|
Total assets |
$ |
446,430 |
|
|
$ |
419,380 |
|
|
Liabilities and Stockholders’ Equity: |
|
|
|
||||
|
Current liabilities: |
|
|
|
||||
|
Accounts payable and accrued expenses |
$ |
41,862 |
|
|
$ |
30,044 |
|
|
Short-term lease liabilities |
|
3,124 |
|
|
|
3,336 |
|
|
Other current liabilities |
|
24,555 |
|
|
|
21,437 |
|
|
Total current liabilities |
|
69,541 |
|
|
|
54,817 |
|
|
Long-term debt, net of current portion |
|
51,794 |
|
|
|
51,913 |
|
|
Long-term lease liabilities |
|
59,918 |
|
|
|
60,919 |
|
|
Other liabilities |
|
6,619 |
|
|
|
5,519 |
|
|
Deferred taxes |
|
1,153 |
|
|
|
965 |
|
|
Total liabilities |
|
189,025 |
|
|
|
174,133 |
|
|
Stockholders’ Equity: |
|
|
|
||||
|
Preferred stock |
|
— |
|
|
|
— |
|
|
Class A common stock |
|
2 |
|
|
|
2 |
|
|
Additional paid-in capital |
|
1,615,501 |
|
|
|
1,596,889 |
|
|
Accumulated deficit |
|
(1,359,003 |
) |
|
|
(1,352,474 |
) |
|
Accumulated other comprehensive income |
|
905 |
|
|
|
830 |
|
|
Total stockholders’ equity |
|
257,405 |
|
|
|
245,247 |
|
|
Total liabilities and stockholders’ equity |
$ |
446,430 |
|
|
$ |
419,380 |
|
|
|
|||||||
|
(1) Other assets includes $990 thousand of restricted cash as of both March 31, 2025 and December 31, 2024. |
|||||||
|
GeneDx Holdings Corp. |
|||||||
|
Condensed Consolidated Statements of Operations (Unaudited) |
|||||||
|
(in thousands, except share and per share amounts) |
|||||||
|
|
|||||||
|
|
Three months ended March 31, |
||||||
|
|
2025 |
|
2024 |
||||
|
Revenue |
|
|
|
||||
|
Diagnostic test revenue |
$ |
85,759 |
|
|
$ |
61,104 |
|
|
Other revenue |
|
1,356 |
|
|
|
1,318 |
|
|
Total revenue |
|
87,115 |
|
|
|
62,422 |
|
|
Cost of services |
|
28,639 |
|
|
|
25,011 |
|
|
Gross profit |
|
58,476 |
|
|
|
37,411 |
|
|
Research and development |
|
12,577 |
|
|
|
11,567 |
|
|
Selling and marketing |
|
18,316 |
|
|
|
16,085 |
|
|
General and administrative |
|
32,134 |
|
|
|
23,419 |
|
|
Loss from operations |
|
(4,551 |
) |
|
|
(13,660 |
) |
|
|
|
|
|
||||
|
Non-operating income (expenses), net |
|
|
|
||||
|
Change in fair value of warrants |
|
(1,100 |
) |
|
|
(6,101 |
) |
|
Interest expense, net |
|
(640 |
) |
|
|
(597 |
) |
|
Other income, net |
|
209 |
|
|
|
37 |
|
|
Total non-operating expenses, net |
|
(1,531 |
) |
|
|
(6,661 |
) |
|
Loss before income taxes |
$ |
(6,082 |
) |
|
$ |
(20,321 |
) |
|
Income tax (expense) benefit |
|
(447 |
) |
|
|
82 |
|
|
Net loss |
$ |
(6,529 |
) |
|
$ |
(20,239 |
) |
|
|
|
|
|
||||
|
Weighted average shares outstanding of Class A common stock |
|
28,147,948 |
|
|
|
26,062,170 |
|
|
Basic and diluted loss per share, Class A common stock |
$ |
(0.23 |
) |
|
$ |
(0.78 |
) |
|
GeneDx Holdings Corp. |
|||||||
|
Condensed Consolidated Statements of Cash Flows (Unaudited) |
|||||||
|
(in thousands) |
|||||||
|
|
|||||||
|
|
Three months ended March 31, |
||||||
|
|
2025 |
|
2024 |
||||
|
Operating activities |
|
|
|
||||
|
Net loss |
$ |
(6,529 |
) |
|
$ |
(20,239 |
) |
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
||||
|
Depreciation and amortization expense |
|
5,678 |
|
|
|
5,248 |
|
|
Stock-based compensation expense |
|
3,983 |
|
|
|
(451 |
) |
|
Change in fair value of warrants |
|
1,100 |
|
|
|
6,101 |
|
|
Deferred tax expense |
|
447 |
|
|
|
(82 |
) |
|
Change in third party payor reserves |
|
1,395 |
|
|
|
(193 |
) |
|
Other |
|
757 |
|
|
|
886 |
|
|
Change in operating assets and liabilities: |
|
|
|
||||
|
Accounts receivable |
|
(8,557 |
) |
|
|
4,220 |
|
|
Inventory |
|
(2,032 |
) |
|
|
(2,877 |
) |
|
Accounts payable and accrued expenses |
|
10,824 |
|
|
|
(4,733 |
) |
|
Other assets and liabilities |
|
3,116 |
|
|
|
(4,293 |
) |
|
Net cash provided by (used in) operating activities |
|
10,182 |
|
|
|
(16,413 |
) |
|
Investing activities |
|
|
|
||||
|
Purchases of property and equipment |
|
(6,129 |
) |
|
|
(443 |
) |
|
Purchases of marketable securities |
|
(17,209 |
) |
|
|
(5,167 |
) |
|
Proceeds from sales of marketable securities |
|
— |
|
|
|
598 |
|
|
Proceeds from maturities of marketable securities |
|
13,930 |
|
|
|
5,855 |
|
|
Net cash (used in) provided by investing activities |
|
(9,408 |
) |
|
|
843 |
|
|
Financing activities |
|
|
|
||||
|
Proceeds from offerings, net of issuance costs |
|
13,894 |
|
|
|
— |
|
|
Exercise of stock options |
|
735 |
|
|
|
24 |
|
|
Long-term debt principal payments |
|
(300 |
) |
|
|
— |
|
|
Finance lease payoff and principal payments |
|
(611 |
) |
|
|
(462 |
) |
|
Net cash provided by (used in) financing activities |
|
13,718 |
|
|
|
(438 |
) |
|
Net increase (decrease) in cash, cash equivalents and restricted cash |
|
14,492 |
|
|
|
(16,008 |
) |
|
Cash, cash equivalents and restricted cash, at beginning of period |
|
86,202 |
|
|
|
100,668 |
|
|
Cash, cash equivalents and restricted cash, at end of period (1) |
$ |
100,694 |
|
|
$ |
84,660 |
|
|
|
|
|
|
||||
|
Supplemental disclosures of cash flow information |
|
|
|
||||
|
Cash paid for interest |
$ |
1,600 |
|
|
$ |
2,019 |
|
|
Cash paid for taxes |
$ |
206 |
|
|
$ |
300 |
|
|
Purchases of property and equipment in accounts payable and accrued expenses |
$ |
2,197 |
|
|
$ |
36 |
|
|
|
|||||||
|
(1) Cash, cash equivalents and restricted cash at March 31, 2025 excludes marketable securities of $59.5 million. |
|||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20250430453841/en/
Contacts
Investor Relations Contact:
Investors@GeneDx.com
Media Contact:
Press@GeneDx.com